PT3326622T - Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática - Google Patents

Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Info

Publication number
PT3326622T
PT3326622T PT171966625T PT17196662T PT3326622T PT 3326622 T PT3326622 T PT 3326622T PT 171966625 T PT171966625 T PT 171966625T PT 17196662 T PT17196662 T PT 17196662T PT 3326622 T PT3326622 T PT 3326622T
Authority
PT
Portugal
Prior art keywords
axl
inhibition
modified
peptides
signaling
Prior art date
Application number
PT171966625T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Univ Leland Stanford Junior
Aravive Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3326622(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior, Aravive Biologics Inc filed Critical Univ Leland Stanford Junior
Publication of PT3326622T publication Critical patent/PT3326622T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT171966625T 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática PT3326622T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
PT3326622T true PT3326622T (pt) 2021-04-07

Family

ID=50934967

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171966625T PT3326622T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
PT138627807T PT2931265T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT138627807T PT2931265T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Country Status (11)

Country Link
US (3) US9822347B2 (https=)
EP (2) EP2931265B3 (https=)
JP (2) JP6345690B2 (https=)
AU (3) AU2013359179B2 (https=)
CA (1) CA2894539C (https=)
DK (2) DK3326622T3 (https=)
ES (2) ES2862335T3 (https=)
FI (1) FI2931265T6 (https=)
NO (1) NO3049208T3 (https=)
PT (2) PT3326622T (https=)
WO (1) WO2014093690A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA2786149C (en) * 2010-01-22 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
PT3326622T (pt) 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
ES2834618T3 (es) * 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6
US20200289613A1 (en) * 2017-11-04 2020-09-17 Aravive Biologics, Inc. Methods of treating metastatic cancers using axl decoy receptors
AU2022343188A1 (en) * 2021-09-11 2024-05-02 Aravive Inc Methods of treating locally advanced or metastatic pancreatic adenocarcinoma using axl decoy receptors as first-line therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030032102A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
WO2004108748A2 (en) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
CA2522984A1 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
JP2008522162A (ja) 2004-11-24 2008-06-26 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド Ｍｅｒの診断用および治療用の作用薬
EP2177614B1 (en) 2005-05-02 2014-12-31 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009005813A1 (en) 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
US20110237498A1 (en) * 2008-12-19 2011-09-29 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
BRPI1013428A2 (pt) 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA2786149C (en) * 2010-01-22 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy
EP2638173B1 (en) 2010-11-08 2019-06-19 The Board of Trustees of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2013090776A1 (en) * 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
PT3326622T (pt) 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
WO2015030849A1 (en) * 2013-08-30 2015-03-05 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
US10137173B2 (en) * 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
ES2834618T3 (es) * 2014-12-18 2021-06-18 Aravive Biologics Inc Actividad antifibrótica del inhibidor de GAS6

Also Published As

Publication number Publication date
FI2931265T6 (fi) 2023-05-23
JP2018154641A (ja) 2018-10-04
EP2931265A1 (en) 2015-10-21
NO3049208T3 (https=) 2018-04-14
AU2019210662B2 (en) 2021-07-01
AU2019210662A1 (en) 2019-08-22
AU2013359179B2 (en) 2017-10-05
US20220220458A1 (en) 2022-07-14
DK2931265T6 (da) 2023-05-01
CA2894539C (en) 2021-09-28
CA2894539A1 (en) 2014-06-19
ES2665323T3 (es) 2018-04-25
WO2014093690A1 (en) 2014-06-19
JP2016510309A (ja) 2016-04-07
ES2665323T7 (es) 2023-06-15
EP3326622A1 (en) 2018-05-30
JP6832887B2 (ja) 2021-02-24
US9822347B2 (en) 2017-11-21
EP3326622B1 (en) 2021-01-20
US11136563B2 (en) 2021-10-05
PT2931265T (pt) 2018-04-16
EP2931265B3 (en) 2023-04-05
JP6345690B2 (ja) 2018-06-20
DK2931265T3 (en) 2018-04-16
US20180030422A1 (en) 2018-02-01
ES2862335T3 (es) 2021-10-07
DK3326622T3 (da) 2021-04-06
EP2931265B1 (en) 2018-01-31
AU2017272193A1 (en) 2017-12-21
US20150315553A1 (en) 2015-11-05
AU2013359179A1 (en) 2015-07-02
EP2931265A4 (en) 2016-08-31
HK1256071A1 (en) 2019-09-13

Similar Documents

Publication Publication Date Title
ZA201307676B (en) Inhibition of axl signaling in anti-metastatic therapy
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
GB201218862D0 (en) Bicyclic heterocycle compounds and their uses in therapy
ZA201307797B (en) Bicyclic heterocycle compounds and their uses in therapy
SG11201406948PA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
PT3326622T (pt) Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
GB201218850D0 (en) Bicyclic heterocycle compounds and their uses in therapy
SG10201609940RA (en) Compounds and their methods of use
GB201218864D0 (en) Bicyclic heterocycle compounds and their uses in therapy
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
EP2806811A4 (en) VERTEBRAL CONSTRUCTION
IL233481A0 (en) Peptides and methods of using them
PL2667880T3 (pl) Oligopeptydy metaloproteinaz i ich zastosowanie terapeutyczne
EP2872208A4 (en) SLEEPING SUPPORTING ARTICLE AND METHOD OF APPLICATION THEREFOR
IL234841A0 (en) Administration forms of halofuginone and methods of use
PL2922557T3 (pl) Suplementy ziołowe i sposoby ich zastosowania
PL2790666T3 (pl) Ekstrakty z maesa japonica i sposoby zastosowania
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
ZA201306861B (en) Outlet fitting basic body and outlet body therefor
GB201219678D0 (en) Ketone body inhibitors and uses thereof
EP2836227A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
PL2744497T3 (pl) Terapeutyczne połączenia netupitantu i palonosetronu
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
EP2877486A4 (en) PEPTIDE-BASED COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BETA-AMYLOID ACCUMULATION